FDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And Adolescents
12/10 05:04
(RTTNews) - Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemop...